Antithrombotic alternatives for stroke prevention in atrial fibrillation: Critical differences and remaining questions

Drugs in Context

Volumn , Issue , 2013, Pages

  Kalus, James S ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Antithrombotic; Apixaban; Atrial fibrillation; Dabigatran; Rivaroxaban; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; CARBAMAZEPINE; CONIVAPTAN; CREATININE; DABIGATRAN; DRONEDARONE; ITRACONAZOLE; KETOCONAZOLE; PHENYTOIN; RIFAMPICIN; RITONAVIR; RIVAROXABAN; WARFARIN;

AREA UNDER THE CURVE; BLEEDING; CEREBROVASCULAR ACCIDENT; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PROTHROMBIN TIME; REVIEW; STROKE PATIENT; THROMBIN TIME; TREATMENT RESPONSE;

EID: 84876360360     PISSN: 17451981     EISSN: 17404398     Source Type: Journal    
DOI: 10.7573/dic.212251     Document Type: Review

References (24)

1. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
2. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
3. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
4. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4.
5. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
6. Wallentin L, Yusuf S, Ezekowitz MD et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83.
7. San TR, Chan MYY, Siong TW et al. Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis 2012, Article ID 108983, 10 pages. doi:10.1155/2012/108983.
8. Pradaxa (dabigatran) prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. December 2012. Available at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf [Last accessed: 24 February 2013].
9. Xarelto (rivaroxaban) prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2011. Available at: http://www.xareltohcp.com/sites/ default/files/pdf/xarelto- 0.pdf#zoom=100 [Last accessed: 24 February 2013].
10. Eliquis (apixaban) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company. December 2012. Available at: http://packageinserts.bms.com/pi/ pi-eliquis.pdf [Last accessed: 24 February 2013].
11. Stangier J, Rathgen K, Stähle H et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-center study. Clin Pharmacokinet 2010;49:259-68.
12. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012;119:2172-4.
13. Harinstein LM, Morgan JW, Russo N. Treatment of dabigatran- associated bleeding: case report and review of the literature. J Pharm Pract 2012 Nov 16 [Epub ahead of print].
14. Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm 2012;69:1473-84.
15. Zhou W, Schwarting S, Illanes S et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011;42: 3594-9.
16. Godier A, Miclot A, Le Bonniec B et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012;116:94-102.
17. van Ryn J, Ruehl D, Priepke H, Havel N, Wienen W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica. 2008; 93(s1):148. Abstract 0370. Available at: http://online.haematologica.org/eha13/browserecord.php?-action= browse&-recid=1923 [Last accessed: 4 January 2013].
18. Gruber A, Marzek UM, Buetehorn U, Hanson S, Perzborn E. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. Blood 2008;112 Abstract 3825. Available at: http://abstracts.hematologylibrary.org/cgi/content/abstract/ 112/11/3825?maxtoshow=&hits=10&RESULTFORMAT=&fulltext= gruber&searchid=1&FIRSTINDEX=0&volume=112&issue= 11&resourcetype=HWCIT [Last accessed: 4 January 2013].
19. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo- controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9.
20. Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012;108:217-24.
21. Blombäck M, He S, Bark N, Wallen HN, Elg M. Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate. Br J Haematol 2001;152:758-65.
22. Freeman JV, Zhu RP, Owens DK et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11.
23. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012;110:845-51.
24. Kamel H, Easton JD, Johnston SC, Kim AS. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology 2012;79:1428-34.